Bakhu Holdings, Corp. 8-K

What Happened
Bakhu Holdings, Corp. filed an 8‑K (June 30, 2026) disclosing material agreements and management changes tied to efforts to restore the company’s regulatory compliance. Key actions include convertible funding agreements with Phytocyte Pty Ltd. (and Inter‑M Traders in an earlier MOU), appointment of Konstantia (Nadia) Galazi as sole director and CEO on March 18, 2026, appointment of Karl E. Watkin as a director on April 10, 2026, and an indemnification letter for former director Efstathios Galazis. A March 17, 2026 MOU (up to $600,000) was later terminated on April 17, 2026; a Binding Heads of Agreement dated April 7, 2026 contemplates up to $250,000 of funding. Both funding arrangements are interest‑free convertible promissory notes that, upon satisfaction of compliance milestones (delinquent SEC filings prepared/filed, fees/taxes paid or provided for, and corporate actions completed), would automatically convert into shares resulting in Phytocyte holding 70% of issued and outstanding common stock.

Key Details

• Phytocyte offered funding via interest‑free convertible notes: an MOU (March 17, 2026) referenced up to $600,000 (later terminated April 17, 2026) and a Binding Heads of Agreement (April 7, 2026) contemplates up to $250,000.
• Conversion condition: upon completion of SEC filings, payment/Provision for auditors’ fees, taxes and compliance costs, the notes would convert so Phytocyte holds 70% of voting common stock (existing shareholders diluted to ~30%).
• Management changes: Konstantia (Nadia) Galazi appointed sole director, President/CEO, Secretary and CFO (March 18, 2026); Karl E. Watkin appointed director (April 10, 2026). Watkin controls Phytocyte and Menelaus Holding FZ LLC.
• Other items: indemnification agreement dated March 18, 2026 for former director Efstathios Galazis; the company is subject to governance restrictions (cannot take major corporate actions without Phytocyte consent while notes are outstanding).

Why It Matters
These filings show Bakhu is pursuing third‑party funding specifically to cure delinquent SEC filings, pay compliance costs and restore good standing. If the funding converts, Phytocyte (controlled by Karl Watkin) would acquire a controlling 70% stake, materially changing board composition and shareholder dilution. Investors should note the direct link between the funding, stringent governance restrictions while funds are outstanding, and the clear path to a potential change of control once compliance milestones are satisfied.